Referring Clinician

Please email all referrals to CentralReferral@adhb.govt.nz (including Att: ACTC in email subject) 

Email us for any other queries: infoACTC@adhb.govt.nz

Tumour StreamTrial NameStudy DescriptionKey Investigational AgentKey Inclusion CriteriaRecruitment Status
Advanced solid tumours with established IO indicationBGB-A317-A445-101Phase 1 Study Investigating the Safety, Tolerability,
Pharmacokinetics, and Preliminary Antitumor Activity of the
Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in
Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab
in Patients With Advanced Solid Tumors
BGB-A445 (OX40 agonist) and Tislelizumab (PD-1 inhibitor)

Three weekly infusions
• Phase 1a: Dose Escalation: Includes BGB-A445 monotherapy cohorts and combination cohorts with tislelizumab. Recruitment opens intermittently.

• Dose Expansion: Closed until phase 1a completed. Details to follow.
Phase 1a recruiting
Metastatic MelanomaMK1308-001 (Checkmate 76U)A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab
Monotherapy and in Combination with Subcutaneous Nivolumab
MK1308A (Co-formulation of MK1308 (CTLA4 inh) + pembrolizumab-Cohort J
o Unresectable stage III or metastatic melanoma
o Confirmed progression on scan after PD1/PDL1 monotherapy or in combination with other therapies excluding prior CTLA4 inhibitor exposure.
o BRAF v600 mutation positive disease accepted provided that participants have/ are still receiving targeted therapy OR remains asymptomatic with no evidence of rapid progression and LDH
ON HOLD